Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.50 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27582475 | 0.87 | GAA (0.52) | GAAHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL20257761 | 0.84 | SLC1A5 (0.55) | GAAHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23004958 | 0.83 | SLC1A5 (0.54) | HTR1AADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL5644007 | 0.83 | SLC1A5 (0.54) | HTR1AADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL19199219 | 0.82 | MAPT (0.51) | GAAHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29278968 | 0.80 | SLC1A5 (0.68) | GAALMNASLC1A5 | |
| SCHEMBL29278966 | 0.80 | SLC1A5 (0.68) | GAALMNASLC1A5 | |
| SCHEMBL9625890 | 0.79 | MAPT (0.55) | HTR1AADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL8283224 | 0.79 | FFAR4 (0.56) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL16579424 | 0.77 | CFD (0.54) | GAAHTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010732-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINE TRANSPORTER ASCT2 AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-11 | — | — | WO | disclosed |
| US-10793514-B2 | Glutamine transport inhibitors and methods for treating cancer | VANDERBILT UNIVERSITY (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200095190-A1 | Glutamine Transport Inhibitors and Methods for Treating Cancer | VANDERBILT UNIVERSITY | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095190-A1 | Glutamine Transport Inhibitors and Methods for Treating Cancer | SLC1A5, SLC7A11, SLC3A2 | GAA 1063/4885HTR1A 3872/4885ADRA1D 4250/4885 |
| US-10793514-B2 | Glutamine transport inhibitors and methods for treating cancer | SLC1A5, SLC7A11, SLC3A2 | GAA 1063/4885HTR1A 3872/4885ADRA1D 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.